What is Avail Pharma?
Avail Pharma operates as a specialized consultancy firm, providing high-level analytical and problem-solving services to the pharmaceutical and biotechnological industries. Established in 1998, the organization has cultivated a deep bench of experts, including former health authority officers, medical writers, and pharmacogenomic specialists. Their core competencies span the entire drug development lifecycle, from regulatory affairs and international medical marketing to complex modeling and simulation. By integrating a multidisciplinary network of external professionals, Avail Pharma delivers bespoke solutions that address the intricate challenges faced by modern life science enterprises, positioning itself as a critical partner for firms navigating the complexities of global market entry and regulatory compliance.
How much funding has Avail Pharma raised?
Avail Pharma has raised a total of $7.1M across 4 funding rounds:
Debt
$125K
Angel/Seed
$750K
Other Financing Round
$2M
Series A
$4.2M
Debt (2013): $125K, investors not publicly disclosed
Angel/Seed (2015): $750K led by Steve Olechowski and Metaprop
Other Financing Round (2017): $2M supported by Sandalphon Capital,, Cultivation Capital, M25 Group, and Charmides Capital
Series A (2020): $4.2M featuring Cultivation Capital
Key Investors in Avail Pharma
Cultivation Capital
Cultivation Capital is a venture capital firm that invests in young companies with transformative ideas across various industries, including life sciences, software, agriculture, and geospatial technology.
M25 Group
M25 Group is a London-based firm that has evolved to meet diverse client needs, providing comprehensive services that emphasize operational order and transparency.
Charmides Capital
Charmides Capital is an Indiana-based venture capital firm specializing in seed and Series A stage funding for high-growth business-to-business software companies.
What's next for Avail Pharma?
With the recent influx of capital, Avail Pharma is well-positioned to scale its service offerings and expand its international footprint. The strategic focus will likely center on enhancing its digital infrastructure for pharmacogenomic data analysis and strengthening its regulatory affairs division to meet the evolving demands of global health authorities. As the company transitions into this next phase of growth, the emphasis will remain on maintaining its high standards of technical excellence while exploring new therapeutic areas. By capitalizing on its established network and deep industry expertise, Avail Pharma is poised to drive further innovation in drug development, ultimately delivering greater value to its clients and stakeholders in the rapidly shifting biotech landscape.
See full Avail Pharma company page
